THE METABOLIC SYNDROME (METS) IN SYMPTOMATIC HEART FAILURE: PREVALENCE AND CLINICAL ASPECTS

2008 ◽  
Vol 19 ◽  
pp. S32
Author(s):  
Daniela Toporan ◽  
Cristina Tanaseanu ◽  
Marius Vintila
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Clinical Aspects ◽  
Symptomatic Heart Failure ◽  
The Metabolic Syndrome

scholarly journals Prognostic Impact of Metabolic Syndrome in Patients With Heart Failure: A Meta-Analysis of Observational Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhuo-Ming Huang ◽  
Wen-Rong Chen ◽  
Qi-Wen Su ◽  
Zhuo-Wen Huang
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Cardiovascular Mortality ◽  
Cardiovascular Events ◽  
Observational Studies ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
The Metabolic Syndrome ◽  
All Cause Mortality ◽  
The Impact

Background: The metabolic syndrome (MS) is significantly associated with the risk of incident heart failure (HF). However, there are still great controversies about the impact of MS on the prognosis in patients with established HF. This meta-analysis aimed to ascertain the effect of MS on the prognosis in patients with HF.Methods: We searched multiple electronic databases, including PubMed, Opengrey, EMBASE, and Cochran Library, for potential studies up to February 15, 2021. Observational studies that reported the impact of MS on the prognosis in patients with established HF were included for meta-analysis.Results: Ten studies comprising 18,590 patients with HF were included for meta-analysis. The median follow-up duration of the included studies was 2.4 years. Compared with HF patients without MS, the risk of all-cause mortality and cardiovascular mortality was not increased in HF with MS (HR = 1.04, 95% CI = 0.88–1.23 for all-cause mortality; HR = 1.66, 95% CI = 0.56–4.88 for cardiovascular mortality, respectively). However, there was a significant increase in composited cardiovascular events in the HF patients with MS compared with those without MS (HR = 1.73, 95% CI = 1.23–2.45).Conclusions: In patients with established HF, the presence of MS did not show an association on the risk of all-cause mortality or cardiovascular mortality, while it may increase the risk of composite cardiovascular events.

scholarly journals Quality of Life and Metabolic Syndrome in Brazilian quilombola communities: A Crosssectional Study

2018 ◽  
Vol 28 (3) ◽  
pp. 316-328
Author(s):  
Luiz Vinicius De Alcantara Sousa ◽  
Erika Da Silva Maciel ◽  
Fernando Rodrigues Peixoto Quaresma ◽  
Ana Carolina Gonçalves de Abreu ◽  
Laércio Da Silva Paiva ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Fasting Blood Glucose ◽  
Clinical Aspects ◽  
Inverse Association ◽  
Male Population ◽  
Female Population ◽  
The Metabolic Syndrome ◽  
Abdominal Perimeter

Introduction: The lifestyle of quilombola communities has changed due to extra community influence, thus affecting their environmental and behavioral factors related to the Metabolic Syndrome (MS). However, little is known about the influence of MS on the Quality of Life (QoL) of quilombola residents. Objective: We aimed to study the association between MS and QoL in quilombola communities in northern Tocantins, Brazil. Methods: The QoL of 147 adults from five quilombola communities from Tocantins was assessed using the WHOQOL-BREF instrument. Blood pressure, abdominal perimeter, fasting blood glucose, triglycerides and HDL-cholesterol were measured, and the presence of MS was defined as the alteration of at least three of these clinical aspects. The association of the clinical components and the SM presence with the Quality of Life was evaluated by Student’s t-test for independent samples. Results: We observed that in the total population, an altered abdominal perimeter had an inverse association with both the Physical (15.2 vs. 14.0, p=0.002) and General QoL domains (14.4 vs. 14.0, p=0.045), and MS was inversely associated with the Physical domain (14.9 vs. 14.0, p=0.030). When stratified by sex, the altered abdominal perimeters in men were inversely associated with the Physical (16.5 vs. 14.4, p<0.001), Environmental (14.0 vs. 12.6, p=0.020) and General domains (15.5 vs. 14.0, p<0.001). MS had an inverse association with the Physical (15.8 vs. 14.4, p=0.026) and General domains (14.8 vs. 14.0 p= 0.042) in men. In women there was no association between any risk factor studied and QoL domain. Conclusions: The status of MS was negatively associated with the quality of life of the male population, highlighting the abdominal perimeter, which influences the Physical and General domains of QoL, but in the female population the MS does not interfere in the perception of QoL. Understanding the relationship between chronic diseases and QoL in quilombola communities is necessary to reduce health inequalities in historically vulnerable communities.  

The metabolic syndrome in heart failure: insights to specific mechanisms

2019 ◽  
Vol 25 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Paola Gargiulo ◽  
Fabio Marsico ◽  
Francesco Renga ◽  
Simona Dell’Aversana ◽  
Immacolata Esposito ◽  
...  
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
The Metabolic Syndrome

Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy

2007 ◽  
Vol 293 (3) ◽  
pp. F670-F679 ◽  
Author(s):  
Jesus Dominguez ◽  
Pengfei Wu ◽  
C. Subah Packer ◽  
Constance Temm ◽  
Katherine J. Kelly
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Renal Injury ◽  
Lipid Accumulation ◽  
Inflammatory Responses ◽  
Overt Nephropathy ◽  
Renal Inflammation ◽  
The Metabolic Syndrome ◽  
Renal Size ◽  
Inflammatory Phenotypes

Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear whether control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF; 10 mg·kg−1·day−1 ip for 14 wk) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.

scholarly journals Sleeping Beauty or the Beast? – The Metabolic Syndrome from an Obstructive Sleep Apnoea Perspective

2010 ◽  
Vol 9 (1) ◽  
pp. 12 ◽  
Author(s):  
Lise Tarnow ◽  
Brigitte Klinkenbijl ◽  
Holger Woehrle ◽  
◽  
◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Obstructive Sleep Apnoea ◽  
Reduce Blood Pressure ◽  
Sleep Apnoea ◽  
Sleeping Beauty ◽  
The Metabolic Syndrome ◽  
Home Based ◽  
Obstructive Sleep

Obstructive sleep apnoea (OSA) is a significant health issue. Patients with cardiovascular disease as well as patients with diabetes have a high prevalence of OSA, and the prevalence of coronary heart disease, heart failure, stroke and diabetes is increased in patients with obstructive sleep apnoea. Physiological responses to OSA include sympathetic activation, neurohumoral changes and inflammation, all of which are precursors for cardiovascular disease and diabetes. International guidelines are starting to recognise the importance of OSA for patients with cardiovascular conditions such as heart failure and hypertension. Diagnosis is important, and home-based sleep testing devices can facilitate this process. Treating OSA with continuous positive airway pressure (CPAP) has been shown to reduce blood pressure (BP) in patients with hypertension, but more research is needed to determine which components of the metabolic syndrome respond best to the addition of CPAP therapy.

Sign in / Sign up

Export Citation Format

Share Document